RESUMO
Although long-term smoking has been associated with chronic kidney disease, its effect on kidney function in early stages has not been clarified. Therefore, the proposed objectives were: (1) to identify subclinical kidney damage in smokers, through a panel of biomarkers; (2) to evaluate the progression of subclinical kidney damage after two years of consumption in these patients; and (3) study whether quitting smoking reduces kidney damage. A prospective study was carried out (patients recruited from a primary care centre and a clinical smoking unit). Kidney function was assessed using a panel of biomarkers and compared between smokers and non-smokers, taking into account potential risk factors for kidney damage. These results show, for the first time in the literature, the relationship between smoking and early (subclinical) kidney damage and provide a panel of biomarkers capable of detecting this condition (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, transferrin, and ganglioside-activating protein GM2). This study also indicates that subclinical damage is maintained when use continues, but can be reversed if patients stop smoking. The use of these biomarkers as diagnostic tools can be a preventive measure in the development of chronic kidney disease associated with smoking and in the prevention of acute events associated with potentially nephrotoxic pharmacological treatment in smokers. Trial registration number: NCT03850756.
RESUMO
INTRODUCTION: Domiciliary oxygen therapy (DOT) is a treatment that requires a high level of cooperation from patients due to the time it takes every day. A high level of non-compliance has been determined among patients receiving DOT. The aim of our study was to assess the level of non-compliance and the influence of active tobacco consumption on compliance. MATERIAL AND METHODS: Patients were monitored in the home using direct and indirect methods, to assess both compliance and tobacco consumption. RESULTS: The level of non-compliance detected by indirect methods was 22.6%, and 66.3% by direct methods. Tobacco consumption determined by indirect methods was 5.8%-8%, depending on the method used, and 16.2% when CO in exhaled air ≥10ppm was established as an indicator of tobacco use. The group of smokers complied with oxygen therapy for a significantly fewer number of hours per day (P<.001) than non-smokers. CONCLUSIONS: There is a high level of therapeutic non-compliance and a significant percentage of patients receiving DOT continue to smoke. Compliance must be monitored, and the correct use of DOT must be emphasized. Additional efforts should also be made to help smokers with DOT to stop smoking, since continued smoking impacts negatively on therapeutic non-compliance.
Assuntos
Oxigenoterapia , Cooperação do Paciente , Poluição por Fumaça de Tabaco , Fumar Tabaco , Idoso , Idoso de 80 Anos ou mais , Poluição do Ar em Ambientes Fechados , Dióxido de Carbono/análise , Estudos Transversais , Feminino , Serviços de Assistência Domiciliar , Humanos , Masculino , Pessoa de Meia-Idade , Oxigenoterapia/instrumentação , Cooperação do Paciente/estatística & dados numéricos , Abandono do Hábito de FumarRESUMO
INTRODUCTION: COPD is a highly prevalent but underdiagnosed disease, due to the limited availability of forced spirometry (FS) in primary care (PC). Microspirometers are inexpensive, easy-to-use devices that can measure FEV6 and FEV1/FEV6, and may help reduce underdiagnosis. The aim of this study was to validate the Piko-6 COPD screening device by demonstrating a good correlation with standard FS. METHODS: FS and Piko-6 determinations were made in 155 patients suspected of having COPD. The correlations, ROC curves, and Youden's index of both methods were compared, taking FS as the gold standard. RESULTS: FEV1, FVC and FEV6 correlation coefficients and FEV1/FVC and FEV1/FEV6 ratios were 0.87 (CI 0.836-0.909), 0.729 (CI 064-0.795) and 0.947 (95% CI 0.928-0.961), respectively. The ROC curve for FEV1 determined by Piko-6 achieved an area under the curve of 0.86 (95% CI: 0.78-0.92). Youden's index with a cut-off point of 0.70 for FEV1/FEV6 was 0.97. CONCLUSIONS: Piko-6 may be useful for COPD screening in PC. Measurements obtained with this device correlate well with those determined by FS, particularly the FEV1/FEV6 ratio. This, combined with its low cost and ease of use, may contribute to reducing COPD underdiagnosis, although its exact role in the diagnostic process remains to be determined.
Assuntos
Atenção Primária à Saúde , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Espirometria/instrumentação , Adulto , Idoso , Idoso de 80 Anos ou mais , Diagnóstico Precoce , Desenho de Equipamento , Feminino , Volume Expiratório Forçado , Humanos , Masculino , Pessoa de Meia-Idade , Doença Pulmonar Obstrutiva Crônica/fisiopatologiaRESUMO
Smoking is, together with diabetes mellitus, one of the main risk factors for cardiovascular disease. Diabetic patients have unique features and characteristics, some of which are not well known, that cause smoking to aggravate the effects of diabetes and impose difficulties in the smoking cessation process, for which a specificand more intensive approach with stricter controls is required. This review details all aspects with a known influence on the interaction between smoking and diabetes, both as regards the increased risk of macrovascular and microvascular complications of diabetes and the factors with an impact on the results of smoking cessation programs. The treatment guidelines for these smokers, including the algorithms and drug treatment patterns which have proved most useful based on scientific evidence, are also discussed.
Assuntos
Diabetes Mellitus/epidemiologia , Abandono do Hábito de Fumar , Fumar/epidemiologia , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , Metilação de DNA/efeitos dos fármacos , Angiopatias Diabéticas/etiologia , Angiopatias Diabéticas/fisiopatologia , Interações Medicamentosas , Humanos , Insulina/farmacocinética , Insulina/fisiologia , Metanálise como Assunto , Neurotransmissores/metabolismo , Nicotina/farmacocinética , Nicotina/farmacologia , Fatores de Risco , Homeostase do Telômero/efeitos dos fármacos , Dispositivos para o Abandono do Uso de Tabaco , Tabagismo/genética , Tabagismo/fisiopatologia , Aumento de PesoRESUMO
The electronic cigarette (EC) is a device formed by three basic elements: battery, atomizer and cartridge. When assembled, it looks like a cigarette. The cartridge contains different substances: propylene glycol, glycerine and, sometimes, nicotine. When the user "vapes", the battery is activated, the atomizer is heated and the liquid is drawn in and vaporized. The smoker inhales the mist produced. Various substances have been detected in this mist: formaldehyde, acetaldehyde and acrolein and some heavy metals. Although these are found in lower concentrations than in cigarettes, they may still be harmful for the human body. Several surveys show that 3-10% of smokers regularly use e-cigarettes. A randomized study has shown that the efficacy of e-cigarettes for helping smokers to quit is similar to nicotine patches. Nevertheless, the study has relevant methodological limitations and reliable conclusions cannot be deduced. This report sets down the Position Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) on the efficacy and safety of e-cigarettes. This statement declares that e-cigarettes should be regulated as medicinal products.
Assuntos
Sistemas Eletrônicos de Liberação de Nicotina , Abandono do Hábito de Fumar/métodos , Adolescente , Sistemas Eletrônicos de Liberação de Nicotina/efeitos adversos , Sistemas Eletrônicos de Liberação de Nicotina/classificação , Sistemas Eletrônicos de Liberação de Nicotina/instrumentação , Sistemas Eletrônicos de Liberação de Nicotina/métodos , Sistemas Eletrônicos de Liberação de Nicotina/estatística & dados numéricos , Desenho de Equipamento , Europa (Continente) , Temperatura Alta , Humanos , Legislação de Dispositivos Médicos , Estudos Multicêntricos como Assunto , Nicotina/administração & dosagem , Nicotina/efeitos adversos , Compostos Orgânicos/efeitos adversos , Compostos Orgânicos/análise , Ensaios Clínicos Controlados Aleatórios como Assunto , Transtornos Respiratórios/induzido quimicamente , Fumaça/análise , Abandono do Hábito de Fumar/legislação & jurisprudência , Soluções/efeitos adversos , Soluções/química , Síndrome de Abstinência a Substâncias/terapia , Estados Unidos , Adulto JovemAssuntos
Doença Pulmonar Obstrutiva Crônica/complicações , Fumar/terapia , Benzazepinas/uso terapêutico , Bupropiona/uso terapêutico , Ensaios Clínicos como Assunto/estatística & dados numéricos , Terapia Cognitivo-Comportamental , Terapia Combinada , Método Duplo-Cego , Seguimentos , Humanos , Motivação , Estudos Multicêntricos como Assunto/estatística & dados numéricos , Avaliação de Programas e Projetos de Saúde , Quinoxalinas/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Recompensa , Índice de Gravidade de Doença , Fumar/psicologia , Abandono do Hábito de Fumar , Espanha , Inquéritos e Questionários , Dispositivos para o Abandono do Uso de Tabaco , Tabagismo/diagnóstico , Tabagismo/tratamento farmacológico , Tabagismo/psicologia , Tabagismo/terapia , VareniclinaRESUMO
BACKGROUND AND OBJECTIVE: School smoking prevention programs have never yielded the expected results. The aim of this study was to analyze the efficacy of an intensive smoking prevention program created by the educational community in which it was to be applied. POPULATION AND METHOD: A 3-year smoking prevention program was carried out among the students of Fuentesaúco Secondary School in Zamora, Spain. The Babilafuente Secondary School in Salamanca, Spain was the control group. The program included both prevention and treatment activities. The former were carried out in the school, in out-of-school situations, and in the community. The questionnaire of the European Smoking Prevention Framework Approach was used. RESULTS: A total of 417 students aged 12 to 17 years participated in the study. Of these, 54.4% belonged to the intervention group and 45.6% to the control group. Smokers represented 36.7% of the population. After the intervention smokers represented 40.1% of the Fuentesaúco students compared with 46.1% of the Babilafuente students, though the difference was not statistically significant. With respect to the cognitive determinants of smoking behavior, after the intervention significant differences in favor of the intervention group were only observed in the subjects' perception of the behavior of their siblings, peers, and teachers. CONCLUSIONS: The use of smoking prevention programs in schools should be reconsidered, and their evaluation should be based on educational rather than clinical criteria. Proposed changes in the program include decreasing its intensity, starting with students of an earlier age and seeking greater involvement of parents.
Assuntos
Prevenção do Hábito de Fumar , Adolescente , Criança , Feminino , Humanos , Masculino , Avaliação de Programas e Projetos de Saúde , Estudos ProspectivosRESUMO
OBJECTIVE: The paucity of long-term studies makes it difficult to evaluate the sustained abstinence over time of smokers who quit. The objective of the present study was to determine to what extent the results of tobacco cessation interventions are maintained after 5 years. PATIENTS AND METHODS: This was a longitudinal prospective study of 502 smokers. The design was quasi-experimental given that therapy was allocated according to the level of the patients' nicotine dependence: routine minimum intervention for smokers with mild addiction and those not in the preparation stage, and nicotine replacement therapy for patients with moderate-to-high dependence and/or a high level of tobacco consumption. RESULTS: Of the 267 patients followed for 5 years, 29.6% quit and were still abstinent at 1 year, and 18.0% remained abstinent after 5 years. Of those who had managed to stop smoking within 2 months of starting the intervention, 47.4% were still abstinent on follow-up at 5 years while 88.1% of those who failed to quit within 2 months were still smoking 5 years later. CONCLUSIONS: The results observed during the action stage could be of use in reorienting the treatment approach, and a planned schedule of follow-up contacts could help patients maintain the abstinence achieved in the course of the intervention.
Assuntos
Nicotina/uso terapêutico , Abandono do Hábito de Fumar , Administração Cutânea , Adulto , Terapia Comportamental , Testes Respiratórios , Monóxido de Carbono/análise , Estudos de Coortes , Terapia Combinada , Aconselhamento , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Nicotina/administração & dosagem , Cooperação do Paciente/estatística & dados numéricos , Avaliação de Programas e Projetos de Saúde , Estudos Prospectivos , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
BACKGROUND AND OBJECTIVE: The objective of the study was to evaluate the effectiveness of the pharmacological treatment of tobacco dependence according to the criteria established by SEPAR. PATIENTS AND METHOD: Longitudinal, prospective and multicentre study. We included smokers aged more than 18 years who attended 5 smokers clinics and received nicotine replacement therapy (NRT), bupropion or both. The punctual and continuous abstinence was studied at the 15, 30, 60, 90 and 180 days with each one of the proposed treatments. Effective results were defined as the intention to treat. RESULTS: There were 904 smokers, 476 males and 428 females, mean age 42.51 (10.09). Of the 904 individuals who started the treatment, 820, 776, 687, 719 and 679 were present at the follow-up sessions at 15, 30, 60, 90 and 180 days, respectively. The punctual global abstinence at 15 and 180 days was 65.6% and 43.1%, while the continuous one was 57.4% and 38.8% at two and six months, respectively. Significant differences were not observed with regard to the punctual or continuous abstinence among patients treated with NRT, bupropion or both. CONCLUSIONS: The pharmacological treatment of tobacco dependence used individually according to the recommendations of the clinical guidelines allows to obtain good results with regard to the momentous and continuous abstinence. The effectiveness of the different first line treatments is similar in all the phases of the therapeutic process.
Assuntos
Antidepressivos de Segunda Geração/uso terapêutico , Bupropiona/uso terapêutico , Nicotina/uso terapêutico , Cooperação do Paciente , Abandono do Hábito de Fumar/métodos , Fumar/tratamento farmacológico , Adulto , Feminino , Humanos , Estudos Longitudinais , Masculino , Estudos Prospectivos , Fatores de TempoRESUMO
BACKGROUND: Smoking is the most important risk factor for public health and one of the factors with the greatest economic repercussions for society. The aim of the present work is to publish the results of a programme to reduce smoking in the working environment. METHODS: A programme was designed in two stages. The first consisted of carrying out a survey to establish the prevalence of smoking and the attitudes towards smoking of staff working for Salamanca district Council. The second stage consisted of a specialized treatment programme for all the workers who wanted to try to give up smoking. RESULTS: A total of 384 workers answered the questionnaire. Of these, 135 (35.1%) were smokers of whom 80.5% (n = 113) wanted to give up smoking and to receive medical help to do so. A total of 73 workers started the programme. After one year of treatment, 41% of the workers who had started the programme had dropped out. An average of 2.9 of every 3 workers found the programme satisfactory. CONCLUSIONS: The prevalence of smoking in Salamanca District Council is similar to that described in the National Health Survey, 1997. Programmes to treat smoking in the working environment are useful to reduce the prevalence of smoking and are welcomed by the workers. Reducing the prevalence of smoking is the first step towards achieving smoke-free institutions.